News
CAPR
10.96
+23.56%
2.09
Notable Wednesday Option Activity: AAP, CAPR, FSLR
NASDAQ · 1h ago
Biotech And Healthcare Stocks Move Higher: KRMD, CARL Surge 24%, AZTA Climbs 23%
NASDAQ · 2h ago
Capricor jumps as Jones upgrades ahead of FDA decision on lead asset
Seeking Alpha · 3h ago
Opco sees Capricor shares moving to $50 on FDA approval
TipRanks · 4h ago
Capricor Therapeutics upgraded to Buy from Hold at Jones
TipRanks · 4h ago
Midday Fly By: CoreWeave reports beat and raise, OpenAI revenue jumps 50% in Q3
TipRanks · 4h ago
Capricor Stock Rises Despite Wider-Than-Expected Q3 Loss
Benzinga · 6h ago
Capricor: The FDA's Objections Change My June Buy To A Sell
Seeking Alpha · 7h ago
Cantor Fitzgerald Sticks to Its Buy Rating for Capricor Therapeutics (CAPR)
TipRanks · 8h ago
Oppenheimer Reaffirms Their Buy Rating on Capricor Therapeutics (CAPR)
TipRanks · 8h ago
Analysts Conflicted on These Healthcare Names: Achieve Life Sciences (QUIT) and Capricor Therapeutics (CAPR)
TipRanks · 9h ago
The Making, Unmaking And Hope Of Capricor Therapeutics (CAPR)
NASDAQ · 11h ago
Capricor (CAPR) Q3 2026 Earnings Call Transcript
The Motley Fool · 18h ago
Capricor Therapeutics shares rise as FDA decision nears
Seeking Alpha · 19h ago
Capricor Therapeutics Q3 2026 Earnings Call Transcript
Benzinga · 23h ago
Capricor Therapeutics GAAP EPS of -$0.73 misses by $0.31
Seeking Alpha · 1d ago
Press Release: Capricor Therapeutics Reports -2-
Dow Jones · 1d ago
*Capricor Therapeutics 3Q Loss/Shr 73c >CAPR
Dow Jones · 1d ago
Here are the major earnings after the close Tuesday
Seeking Alpha · 1d ago
Weekly Report: what happened at CAPR last week (1102-1106)?
Weekly Report · 2d ago
More
Webull provides a variety of real-time CAPR stock news. You can receive the latest news about Capricor Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.